Dheer Health Care Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Dheer Health Care Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $182.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Dheer Health Care Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $182.4K Trade | TransData Nexus

Dheer Health Care Private Limited

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $182.4K Total Trade · DGFT Verified

Dheer Health Care Private Limited is an Indian pharmaceutical exporter with a total trade value of $182.4K across 3 products in 2 therapeutic categories. Based on 11 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Sulfasalazine ($103.7K), Mitomycin ($44.3K), Dacarbazine ($34.4K).

Dheer Health Care Private Limited — Export Portfolio & Destination Treemap

Dheer Health Care Private Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Dheer Health Care Private Limited? — Company Overview & Market Position

Dheer Health Care Private Limited is a privately held pharmaceutical company established on September 15, 2015, in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U33111MH2015PTC268436. Its authorized share capital is ₹1,000,000, with a paid-up capital of ₹100,000. The registered office is located at Office No. 904, 905 & 906, 9th Floor, Sunshine Tower, Senapati Bapat Marg, Dadar-West, Mumbai, Maharashtra, 400013.

Dheer Health Care specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio is concentrated, with its top five products accounting for 100% of its export value. In the fiscal year 2023, the company experienced a 9.45% decrease in revenue and a 14.11% decline in profit, while its net worth increased by 28.38%.

What Does Dheer Health Care Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Sulfasalazine$103.7K 2

Product Portfolio — Top 3 by Export Value

Dheer Health Care Private Limited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Sulfasalazine	Gastrointestinal	$103.7K	3	3.2%	8
2	Mitomycin	Advanced Oncology	$44.3K	5	0.5%	10
3	Dacarbazine	Advanced Oncology	$34.4K	3	2.4%	12

Dheer Health Care Private Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $182.4K. The top category is Gastrointestinal (56.8% of portfolio), followed by Advanced Oncology (43.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Dheer Health Care Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Dheer Health Care's manufacturing facilities are not publicly disclosed. The company operates as an exporter and trader of pharmaceutical products, suggesting that its manufacturing processes may be outsourced to third-party contract manufacturers. This approach is common in the pharmaceutical industry, allowing companies to focus on distribution and market expansion while leveraging the manufacturing capabilities of specialized facilities.

3Key Leadership

The company's leadership comprises two directors:

Kamlesh Ghisulal Jain: Director since September 15, 2015.

Atish Ghisulal Jain: Director since September 15, 2015.

Both directors have been associated with the company since its inception, indicating a stable leadership structure. Their roles encompass strategic decision-making and overseeing the company's operations, particularly in the export and distribution of pharmaceutical products.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Dheer Health Care Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Dheer Health Care's export data indicates a focus on markets within the gastrointestinal and advanced oncology therapeutic categories. However, specific information regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan is not publicly available. This lack of transparency may be due to the company's reliance on third-party manufacturers and distributors, which can complicate the disclosure of regulatory compliance details.

2Emerging Markets

Dheer Health Care's export activities are not detailed in terms of specific emerging markets such as Africa, Latin America, and Southeast Asia. The company's focus on gastrointestinal and oncology products suggests potential interest in regions with a high prevalence of these conditions. However, without explicit information on WHO prequalification or other certifications, it is challenging to assess the company's penetration and market access in these regions.

3Geographic Strategy

The company's export portfolio is highly concentrated, with its top five products accounting for 100% of its export value. This indicates a focused geographic strategy, potentially targeting markets with high demand for these specific therapeutic categories. While this approach can lead to strong market positions in selected regions, it also exposes the company to risks associated with market fluctuations and regulatory changes in these areas.

Dheer Health Care Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Dheer Health Care's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's reliance on third-party manufacturers may contribute to the lack of transparency in this area. Without direct FDA approvals, the company may face challenges in entering the U.S. market, as FDA approval is typically required for the sale of pharmaceutical products in the United States.

2WHO & EU GMP

There is no publicly available information indicating that Dheer Health Care holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. These certifications are crucial for accessing international markets, particularly in regions with stringent regulatory standards. The absence of such certifications may limit the company's ability to expand its presence in these markets.

3CDSCO & Indian Regulatory

Dheer Health Care is registered with the Ministry of Corporate Affairs (MCA) under the Corporate Identification Number (CIN) U33111MH2015PTC268436. The company's authorized share capital is ₹1,000,000, with a paid-up capital of ₹100,000. Specific details regarding manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. The company's reliance on third-party manufacturers may contribute to the lack of transparency in this area.

Dheer Health Care Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Dheer Health Care operates in the pharmaceutical export sector, focusing on gastrointestinal and oncology products. The company's top competitors in these therapeutic categories include established pharmaceutical exporters with a global presence. However, without specific market share data, it is challenging to provide a detailed head-to-head analysis. The company's reliance on third-party manufacturers may also impact its competitiveness, as it may face challenges in ensuring consistent product quality and meeting regulatory standards.

2Key Differentiators

Dheer Health Care's key differentiators include its focus on specific therapeutic categories, such as gastrointestinal and oncology products, and its extensive distribution network. The company's commitment to quality management and timely deliveries contributes to customer satisfaction. However, the lack of direct manufacturing capabilities and regulatory certifications may limit its ability to differentiate itself in certain markets.

3Strategic Position

Dheer Health Care's current strategic direction appears to be focused on exporting a concentrated portfolio of gastrointestinal and oncology products. The company's reliance on third-party manufacturers allows it to offer a wide range of products without the need for in-house manufacturing facilities. However, the absence of direct regulatory approvals and certifications may pose challenges to its future growth and market expansion. To enhance its strategic position, the company may consider obtaining necessary regulatory approvals and certifications to access a broader range of markets.

Buyer Due Diligence Brief — Evaluating Dheer Health Care Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Dheer Health Care's track record as an exporter is characterized by a focused product portfolio and a commitment to quality management. The company's reliance on third-party manufacturers necessitates a thorough assessment of these suppliers to ensure consistent product quality and compliance with regulatory standards. Indicators of reliability include the suppliers' certifications, inspection histories, and adherence to international quality standards.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the product is approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. Verification can be done through the FDA's official website or by contacting the manufacturer directly.

WHO-GMP Certification: Ensure that the manufacturing facility holds World Health Organization Good Manufacturing Practice (WHO-GMP) certification. This can be verified by checking the WHO's official list of prequalified manufacturers.

Frequently Asked Questions — Dheer Health Care Private Limited

How many pharmaceutical products does Dheer Health Care Private Limited export from India?

Dheer Health Care Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Sulfasalazine ($103.7K), Mitomycin ($44.3K), Dacarbazine ($34.4K). Total export value is $182.4K.

What is Dheer Health Care Private Limited's total pharmaceutical export value?

Dheer Health Care Private Limited's total pharmaceutical export value is $182.4K, based on 11 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Dheer Health Care Private Limited cover?

Dheer Health Care Private Limited exports across 2 therapeutic categories. The largest are Gastrointestinal (56.8%, 1 products), Advanced Oncology (43.2%, 2 products).

Get Full Dheer Health Care Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.